Information Provided By:
Fly News Breaks for October 24, 2016
LLY
Oct 24, 2016 | 07:35 EDT
SunTrust analyst John Boris expects Eli Lilly's Q3 results to beat expectations, driven by higher than expected Trulicity sales. The analyst expects sales of the company's Jardiance drug to accelerate due to a CV benefit that will be added to its label, and he says that the company's oncology business will be boosted by the launch of Olaratumab in Q4 and new data on abemaciclib. The analyst keeps a $107 price target and a Buy rating on Eli Lilly.
News For LLY From the Last 2 Days
There are no results for your query LLY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.